Sharps Technology Inc., (STSS) News
Filter STSS News Items
STSS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest STSS News From Around the Web
Below are the latest news stories about SHARPS TECHNOLOGY INC that investors may wish to consider to help them evaluate STSS as an investment opportunity.
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $5.6 Million Registered Direct & Private Placement Priced at the Market Under Nasdaq Rules for Sharps Technology, Inc. (NASDAQ: STSS)NEW YORK, NY / ACCESSWIRE / September 29, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.6 Million Registered Direct & Private Placement Priced at the Market Under Nasdaq Rules for Sharps Technology, Inc. (NASDAQ:STSS).About ... |
Sharps Technology Announces Closing of $5.6 Million Registered Direct and Private PlacementNEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced registered direct offering and concurrent private placement with institutional investors. The Company issued 4,418,521 shares of common stock and pre-funded warrants to acquire common stock in a registered direct |
Sharps Technology, Reviva Pharmaceuticals, and American Resources Corp. Interviews to Air on the RedChip Money Report(R) on Bloomberg TVORLANDO, FL / ACCESSWIRE / September 29, 2023 / RedChip Companies will air interviews with Sharps Technology, Inc. (NASDAQ:STSS), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and American Resources Corp. (NASDAQ:AREC) on The RedChip Money Report®, ... |
Sharps Technology Issues Letter to Shareholders Covering the Announced Asset Purchase Agreement to Acquire InjectEZ Prefillable Syringe Manufacturing Facility and the Associated $400 Million 10-Year Purchase Agreement with Nephron PharmaceuticalsTransformative acquisition and purchase order enables Sharps to commercialize its innovative copolymer prefillable syringe systems to the healthcare market Company has a capitalization strategy through debt that has resulted in a signed term sheet with a leading middle-market lender for up to $75 Million NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best- |
UPDATE - Sharps Technology Announces $5.6 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq RulesNEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale of 4,418,521 shares of common stock and pre-funded warrants to acquire common stock in a registered direct offering. The purchase price of each share |
Sharps Technology Announces $5.6 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq RulesNEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale of 4,418,521 shares of common stock and pre-funded warrants to acquire common stock in a registered direct offering. The purchase price of each share |
Sharps Technology Signs Asset Purchase Agreement to Acquire InjectEZ Specialty Copolymer Syringe Manufacturing Facility and a 10-Year Purchase Agreement for Over $400 Million from Nephron Pharmaceuticals$50 Million acquisition of InjectEZ strengthens manufacturing capacity and establishes Sharps’ leading position in the specialized copolymer prefillable syringe system industry Signed term sheet providing for up to $75 Million in debt financing to be used for the acquisition Nephron commits to minimum orders of over $400 Million over 10 years; $30 Million in revenue the first year and subsequent minimum orders totaling over $45 Million in annual revenue through December of 2033 NEW YORK and WEST |
Sharps Technology, Inc. CEO is Featured in an Interview with SmallCapsDailyNEW YORK, NY - (NewMediaWire) - September 22, 2023 - Sharps Technology, Inc. (NASDAQ: STSS), is pleased to announce its CEO, Robert Hayes, recently conducted an interview with SmallCapsDaily providing insights into the Company's innovative drug deliv... |
RedChip Launches 'Small Stocks, Big Money' PodcastRedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap companies,announce the launch of its much-anticipated podcast series, "Small Stocks, Big Money." |
Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of SalesKey appointment with demonstrated experience in leading sales and marketing operations to oversee commercial initiatives as the Company launches its specialty smart safety syringe products to the market Product qualification and sales initiatives underway as company prepares for U.S. commercial operations NEW YORK, July 12, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best- |